The economic implications of cyclooxygenase-2–specific inhibitors
- 19 February 2001
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 110 (3) , 50-54
- https://doi.org/10.1016/s0002-9343(01)00619-2
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritisClinical Therapeutics, 1999
- Impact of NSAID choice and patient symptoms on the cost-effectiveness of strategies to prevent NSAID gastropathyGastroenterology, 1998
- Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. The importance of drug and surgery costsArthritis & Rheumatism, 1997
- The impact of disabling arthritisArthritis & Rheumatism, 1995
- Economic and Quality-of-Life Impact of NSAIDs in Rheumatoid ArthritisPharmacoEconomics, 1995
- Special article the economic cost and social and psychological impact of musculoskeletal conditionsArthritis & Rheumatism, 1995
- Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial.Gut, 1995
- A Cost‐Utility Analysis of Misoprostol Prophylaxis for Rheumatoid Arthritis Patients Receiving Nonsteroidal Antiinflammatory DrugsArthritis & Rheumatism, 1994
- The cost‐effectiveness of misoprostol for nonsteroidal antiinflammatory drug–associated adverse gastrointestinal eventsArthritis & Rheumatism, 1993